HER2 testing in gastric cancer: An update

被引：186
|
作者：
Abrahao-Machado, Lucas Faria [1 ]
Scapulatempo-Neto, Cristovam [1 ]
机构：
[1] Barretos Canc Hosp, Dept Pathol, Rua Antenor Duarte Villela 1331, BR-14784400 Barretos, SP, Brazil
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2016年 / 22卷 / 19期
关键词：
Human epidermal growth factor receptor 2 testing; Gastric cancer; Immunohistochemistry; Scoring system; Trastuzumab; IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; HELICOBACTER-PYLORI; SCORING SYSTEM; EXPRESSION; FISH; VALIDATION; PROGNOSIS; CARCINOMA; OVEREXPRESSION;
D O I：
10.3748/wjg.v22.i19.4619
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer. With the recent introduction of HER2 molecular targeted therapy for patients with advanced gastric cancer, determination of HER2 status is crucial in order to select patients who may benefit from this treatment. This paper provides an update on our knowledge of HER2 in gastric and gastroesophageal cancer, including the prognostic relevance of HER2, the key differences between HER2 protein expression interpretation in breast and gastric cancer, the detection methods and the immunohistochemistry scoring system.
引用
收藏
页码：4619 / 4625
页数：7
相关论文
共 50 条
  • [41] HER2 positive gastric cancer: Who benefits from HER2 targeted therapy?
    Kolbe, K.
    Haffner, I.
    Schierle, K.
    Maier, D.
    Geier, B.
    Luber, B.
    Kretzschmar, A.
    von Weikersthal, Fischer L.
    Ahlborn, M.
    Riera, J.
    Rau, B.
    Siegler, G.
    Fuxius, S.
    Decker, T.
    Wittekind, C.
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 156 - 157
  • [42] HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
    Gomez-Martin, Carlos
    Garralda, Elena
    Jose Echarri, M.
    Ballesteros, Anabel
    Arcediano, Alberto
    Luis Rodriguez-Peralto, Jose
    Hidalgo, Manuel
    Lopez-Rios, Fernando
    JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (08) : 751 - 757
  • [43] What are NCI-designated cancer centers using for gastric and esophageal cancer HER2 testing?
    Trosman, Julia R.
    Weldon, Christine B.
    Tsongalis, Gregory J.
    Schink, Julian C.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] HER2 as a therapeutic target in the gastric cancer: is it sufficient?
    Chaturvedi, Rupesh
    Singh, Amar
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2012, 31 (03) : 103 - 105
  • [45] HER2 targeting therapy for advanced gastric cancer
    Shitara, Kohei
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] HER2 in Resected Gastric Cancer: Is there Prognostic Value?
    Fisher, Sarah B.
    Fisher, Kevin E.
    Squires, Malcolm H., III
    Patel, Sameer H.
    Kooby, David A.
    El-Rayes, Bassel F.
    Cardona, Kenneth
    Russell, Maria C.
    Staley, Charles A., III
    Farris, Alton B., III
    Maithel, Shishir K.
    JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (02) : 61 - 66
  • [47] HER2 therapies and gastric cancer: A step forward
    de Mello, Ramon Andrade
    Marques, Andrea Marin
    Araujo, Antonio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (37) : 6165 - 6169
  • [48] HER2 as a therapeutic target in the gastric cancer: is it sufficient?
    Rupesh Chaturvedi
    Amar B. Singh
    Indian Journal of Gastroenterology, 2012, 31 (3) : 103 - 105
  • [49] HER2 therapies and gastric cancer:A step forward
    Ramon Andrade de Mello
    Andrea Marin Marques
    António Araújo
    World Journal of Gastroenterology, 2013, 19 (37) : 6165 - 6169
  • [50] HER2 polymorphism is associated with gastric cancer risk
    Pinto, D.
    Faustino, C.
    Ferreira, P.
    Teixeira, A. L.
    Pinto-Correia, A. L.
    Sousa, H.
    Dinis-Ribeiro, M.
    Fragoso, M.
    Medeiros, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 64 - 64
12345